Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma

Clinical Cancer Research

Volumn 16, Issue 11, 2010, Pages 2971-2978

  Buckley, Patrick G ^a,b   Alcock, Leah ^a,b   Bryan, Kenneth ^a,b   Bray, Isabella ^a,b   Schulte, Johannes H ^c   Schramm, Alexander ^c   Eggert, Angelika ^c   Mestdagh, Pieter ^d   De Preter, Katleen ^d   Vandesompele, Jo ^d   Speleman, Frank ^d   Stallings, Raymond L ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 4P; CHROMOSOME 7Q; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DOWN REGULATION; EVENT FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; NEUROBLASTOMA; PRIORITY JOURNAL; UPREGULATION;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; DISEASE-FREE SURVIVAL; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; NEUROBLASTOMA;

EID: 77953114650     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3215     Document Type: Article

References (44)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216
2. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-1124 (Pubitemid 14106392)
3. Van Roy N, Laureys G, Cheng NC, et al. 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 1994;10: 103-114
4. Guo C, White PS, Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999;18: 4948-4957
5. Plantaz D, Vandesompele J, Van Roy N, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 2001;91:680-686
6. Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res 2003;9:52-58 (Pubitemid 36109715)
7. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353: 2243-2253
8. Vandesompele J, Van Roy N, Van Gele M, et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer 1998;23:141-152
9. Breen CJ, O'Meara A, McDermott M, Mullarkey M, Stallings RL. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization. Cancer Genet Cytogenet 2000;120:44-49
10. Stark B, Jeison M, Glaser-Gabay L, et al. der(11)t(11;17): a distinct cytogenetic pathway of advanced stage neuroblastoma (NBL) - detected by spectral karyotyping (SKY). Cancer Lett 2003;197:75-79
11. Stallings RL, Carty P, McArdle L, et al. Molecular cytogenetic analysis of recurrent unbalanced t(11;17) in neuroblastoma. Cancer Genet Cytogenet 2004;154:44-51.
12. McArdle L, McDermott M, Purcell R, et al. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis 2004;25:1599-1609
13. Wang Q, Diskin S, Rappaport E, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006;66:6050-6062
14. Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007;67:976-983
15. Vandesompele J, Baudis M, De Preter K, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005;23:2280-2299
16. Michels E, Vandesompele J, De Preter K, et al. ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 2007;46:1098-1108
17. Mosse YP, Diskin SJ, Wasserman N, et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 2007;46: 936-949
18. Mestdagh P, Feys T, Bernard N, et al. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 2008;36:e143.
19. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 2009;10:R64.
20. Selzer RR, Richmond TA, Pofahl NJ, et al. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 2005; 44:305-319
21. Workman C, Jensen LJ, Jarmer H, et al. A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol 2002;3:research0048.
22. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008;36:D154-8.
23. Stallings RL, Nair P, Maris JM, et al. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 2006;66:3673-3680
24. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340:1954-1961
25. Bown N, Lastowska M, Cotterill S, et al,U.K.Cancer Cytogenetics GroupU.K.Children'sCancer Study Group. 17q gain in neuroblastoma predicts adverse clinical outcome. Med Pediatr Oncol2001;36:14-19
26. Brinkschmidt C, Christiansen H, Terpe HJ, et al. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol 2001;36:11-13
27. Spitz R, Hero B, Ernestus K, Berthold F. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin Cancer Res 2003;9:4835-4840 (Pubitemid 37323287)
28. Jelinek DF, Tschumper RC, Stolovitzky GA, et al. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 2003;1:346-361 (Pubitemid 36437921)
29. Hu Y, Wang M, Veverka K, Garcia FU, Stearns ME. The ABCA5 protein: a urine diagnostic marker for prostatic intraepithelial neoplasia. Clin Cancer Res 2007;13:929-938
30. Bera TK, Iavarone C, Kumar V, Lee S, Lee B, Pastan I. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc Natl Acad Sci U S A 2002; 99:6997-7002.
31. Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002;20:11-20.
32. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-974
33. Kumar U, Grigorakis SI, Watt HL, et al. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 2005;92:175-186
34. Negishi M, Oinuma I, Katoh H. Plexins: axon guidance and signal transduction. Cell Mol Life Sci 2005;62:1363-1371
35. Gandellini P, Folini M, Longoni N, et al. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cε. Cancer Res 2009;69:2287-2295
36. Iorio MV, Casalini P, Piovan C, et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009;69:2195-2200
37. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from non-squamous non-small-cell lung carcinoma. J Clin Oncol 2009;27: 2030-2037
38. Bray I, Bryan K, Prenter S, et al. Widespread dysregulation of miRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 2009;4:e7850.
39. Fischer M, Bauer T, Oberthur A, et al. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 2009;29:865-875
40. Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-5078
41. Vermeulen J, De Preter K, Naranjo A, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10: 663-671
42. Mestdagh P, Fredlund E, Pattyn F, et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2009.
43. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-1033
44. Schleiermacher G, Michon J, Huon I, et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer 2007;97:238-246